When measuring CBF, it was found that in CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, and synaptic dysfunction, highlighting that CBF reduction occurs early in the AD continuum [25]. The gene discussed is MAPT; the disease is Alzheimer disease.